Protalix BioTherapeutics, a commercial-stage biopharmaceutical firm specializing in plant cell-based recombinant protein therapies, reported a slight decline in revenue to $52.7 million in FY2025 along with a net loss of $6.6 million, reflecting increased costs and operating challenges. Its business centers on enzyme replacement therapies for rare diseases, marketed globally through key collaborations with Pfizer, Chiesi, and Fiocruz. Meanwhile, pipeline expansion efforts focus on rare kidney conditions with PRX-115 advancing into Phase 2 clinical trials. The company’s proprietary ProCellEx® platform and extensive patent portfolio underpin its competitive moat, but regulatory uncertainties and geopolitical risks in Israel remain notable threats to near-term growth and operational stability.